Perfil de fragilidade excluindo o padrão FOLFOX+nivo/FLOT no câncer gástrico: ECOG ≥3, OR (ag...
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | RF-GASTRIC-FRAILTY-AGE |
|---|---|
| Tipo | Sinal de alerta |
| Estado | reviewed 2026-04-26 | pending_clinical_signoff |
| Doenças | DIS-GASTRIC |
| Fontes | SRC-ESMO-GASTRIC-2024 SRC-NCCN-GASTRIC-2025 |
Origem da bandeira vermelha
| Definição | Frailty profile precluding standard FOLFOX+nivo / FLOT in gastric cancer: ECOG ≥3, OR (age ≥75 + Charlson ≥3), OR composite (age ≥70 + albumin <3.0 + ≥10% weight loss + sarcopenia — common in gastric cancer). Triggers regimen de-escalation (5-FU / capecitabine monotherapy, omit ICI/biologic). |
|---|---|
| Direcção clínica | de escalonamento |
| Categoria | Idade de fragilidade |
Lógica de Desencadeamento
{
"any_of": [
{
"comparator": ">=",
"finding": "ecog",
"threshold": 3
},
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 70
},
{
"comparator": "<",
"finding": "albumin_g_dl",
"threshold": 3.0
},
{
"comparator": ">=",
"finding": "weight_loss_pct_3mo",
"threshold": 10
}
]
}
],
"type": "composite_score"
}
Notas
Pre-treatment nutrition optimization (PEG/J-tube, parenteral nutrition bridge) often required. Nivolumab-containing regimens have lower symptomatic toxicity than FLOT for elderly — ATTRACTION-4 included ECOG 0-1 only; real-world frail elderly: capecitabine + nivolumab is reasonable de-escalation.
Usado por
Indicação
IND-GASTRIC-METASTATIC-1L-CLDN18-2-ZOLBETUXIMAB- IND-GASTRIC-METASTATIC-1L-CLDN18-2-ZOLBETUXIMABIND-GASTRIC-METASTATIC-1L-FGFR2B-BEMARITUZUMAB- IND-GASTRIC-METASTATIC-1L-FGFR2B-BEMARITUZUMABIND-GASTRIC-METASTATIC-1L-HER2-TOGA- IND-GASTRIC-METASTATIC-1L-HER2-TOGAIND-GASTRIC-METASTATIC-2L-HER2-TDXD- IND-GASTRIC-METASTATIC-2L-HER2-TDXDIND-GASTRIC-METASTATIC-2L-RAMUCIRUMAB-PACLITAXEL- IND-GASTRIC-METASTATIC-2L-RAMUCIRUMAB-PACLITAXELIND-GASTRIC-METASTATIC-3L-TAS102- IND-GASTRIC-METASTATIC-3L-TAS102